Exercise and Inflammation in the Elderly (IRIS)

This study is ongoing, but not recruiting participants.
University of Maryland
Johns Hopkins University
Information provided by (Responsible Party):
VA Office of Research and Development
ClinicalTrials.gov Identifier:
First received: September 12, 2008
Last updated: August 4, 2015
Last verified: August 2015
Persistent low-grade inflammation and impaired fibrinolysis, are independent predictors of several chronic diseases highly prevalent in the older veteran population including cardiovascular disease (CVD), stroke, and diabetes. Inflammation is likely to be a causative underlying mechanism of insulin resistance. Lifestyle changes such as weight loss and physical activity are advocated for the treatment of these chronic diseases and endpoints, and data are emerging which suggest that these treatments may be beneficial, in part, due to their anti-inflammatory effects. Identification of effective therapies that reduce chronic inflammation for veterans is important given the widespread adverse health effects of a chronically elevated inflammatory state.

Condition Intervention
Insulin Sensitivity
Other: Weight Loss
Other: Aerobic Exercise Training

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Exercise, Inflammation and Pro-thrombotic Modulators in the Elderly

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Primary Outcome Measures:
  • Insulin Sensitivity [ Time Frame: Baseline and 6 month ] [ Designated as safety issue: No ]
    Insulin resistance is defined as a reduction in glucose utilization rate elicited by a given insulin concentration. Glucose utilization is measured during a three hour hyperinsulinemic-euglycemic clamp and is presented as a measure of insulin sensitivity. This is one of the most sophisticated methods to measure insulin sensitivity.

Secondary Outcome Measures:
  • Body Weight [ Time Frame: Baseline and 6 month ] [ Designated as safety issue: No ]
  • Fitness [ Time Frame: Baseline and 6 month ] [ Designated as safety issue: No ]
    Maximal oxygen consumption (VO2max) on a treadmill

Enrollment: 119
Study Start Date: April 2007
Estimated Study Completion Date: November 2016
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
6 months of aerobic exercise training
Other: Aerobic Exercise Training
6 months of aerobic exercise training
Experimental: Arm 2
6 months of weight loss
Other: Weight Loss
6 months of weight loss

Detailed Description:

This study will compare the effects of 6 month trial of aerobic exercise (AEX) vs. weight loss (WL) in older individuals on:

  1. adipokine secretion and expression (tumor necrosis factor alpha, adiponectin);
  2. adipose tissue and skeletal muscle inflammatory proximal receptor expression (adiponectin and tumor necrosis factor alpha expression) and intermediate and terminal signaling pathways; and
  3. whether the changes in ligand concentrations, receptor expression, and signal transduction are associated with changes in peripheral whole body insulin sensitivity by a hyperinsulinemic-euglycemic clamp.

The prevention and treatment of insulin resistance, the metabolic syndrome, and their CVD complications through exercise and weight loss could improve veterans' health and reduce health care costs. Knowledge of their effectiveness has important implications for the cardiovascular health of veterans given the widespread adverse health effects of chronic inflammation on vascular biology, skeletal muscle function and insulin action.


Ages Eligible for Study:   45 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and Female
  • 45-80 yrs of age
  • Non-smoking for one year
  • Body mass index greater than 20 kg/m2 and less than 50 kg/m2
  • Menopause over 1 year

Exclusion Criteria:

  • Symptomatic heart disease, coronary artery disease, congestive heart failure, or uncontrolled hypertension (blood pressure over 180/100 mm Hg) unless medically stabilized
  • Currently being treated for active cancer
  • Type 1 diabetes; Insulin or oral agent treatment for diabetes, poorly controlled diabetes fasting blood glucose over 160 mg/dl
  • Allergic to lidocaine
  • Untreated dyslipidemia with National Cholesterol Adult Treatment Panel III 10 year cardiac risk score greater than 10%, or receiving triglyceride lowering meds
  • Other systemic disorders that are not medically treated and stable
  • Taking beta-blockers, oral steroids, warfarin or any other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (ie for 72 hours prior)
  • Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120mm Hg, or other contraindications to exercise) *requires follow up treatment w/ primary MD for continued participation in study
  • Abnormal liver function
  • Abnormal renal function
  • Chronic pulmonary disease
  • Anemia hematocrit below 35 mg/dl, platelets below 100,000/cm3
  • Mini-mental state exam below 24, dementia or unstable clinical depression by exam
  • Aerobically trained with maximal oxygen consumption greater than 2 standard deviations above age-adjusted mean
  • Exercise group only: History of cerebrovascular disease (by medical history) with symptoms limiting the ability to exercise
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00753363

United States, Maryland
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
VA Office of Research and Development
University of Maryland
Johns Hopkins University
Principal Investigator: Alice S Ryan, PhD Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
  More Information

No publications provided

Responsible Party: VA Office of Research and Development
ClinicalTrials.gov Identifier: NCT00753363     History of Changes
Other Study ID Numbers: AGCG-003-05F
Study First Received: September 12, 2008
Results First Received: October 15, 2014
Last Updated: August 4, 2015
Health Authority: United States: Federal Government

Keywords provided by VA Office of Research and Development:
Glucose Metabolism

Additional relevant MeSH terms:
Pathologic Processes

ClinicalTrials.gov processed this record on November 25, 2015